Jefferies rates Standard BioTools stock 'Buy', eyes platform's growth potential

On Thursday, Jefferies initiated coverage on Standard BioTools Inc (NASDAQ: LAB) stock with a Buy rating, setting a price target of $3.25. The firm highlighted the company's strategic focus on developing a technology platform that is poised for scalability and profitability.

The recent acquisition by Standard BioTools of a complementary business in the multi-omics space is seen as a significant move that accelerates the company's expansion and enhances its position in the lucrative biopharmaceutical market.

The analyst from Jefferies praised the operational progress made by Standard BioTools' legacy business, attributing the success to the strong management team, which has experience from Danaher Corporation (NYSE:DHR). This foundation is expected to support further advancements in the company's performance.

The price target of $3.25 is based on approximately 4.5 times the company's projected 2025 revenues. The slight premium on the price target is justified by Standard BioTools' robust gross margins. The analyst anticipates that as the company continues to execute its business plan and provides greater clarity on its mid-term profitability, there could be a potential re-rating of the stock's multiple.

As Standard BioTools Inc (NASDAQ: LAB) garners a positive outlook from Jefferies with a Buy rating and a price target of $3.25, insights from InvestingPro provide a nuanced view of the company's financial health and stock performance. According to real-time data, Standard BioTools has a market capitalization of $1.02 billion, indicating a significant presence in the biotech tools market. Despite the optimism, the company's P/E ratio stands at -2.82, reflecting challenges in profitability, with analysts not expecting the company to be profitable this year. This aligns with an adjusted P/E ratio for the last twelve months as of Q4 2023 at -14.84, further indicating investor skepticism about near-term earnings.

Nevertheless, Standard BioTools exhibits a strong return over the last three months of 37.82%, which may interest investors looking for short-term gains. The company's revenue growth of 8.57% in the last twelve months, coupled with a gross profit margin of 47.44%, suggests that Standard BioTools is maintaining a healthy top-line growth and profitability at the gross level, despite the anticipated drop in net income. Two InvestingPro Tips highlight that while the stock price movements are quite volatile, there has been a large price uptick over the last six months, suggesting a potential for capital appreciation.

For those looking to delve deeper into the financials and future outlook of Standard BioTools, InvestingPro offers more comprehensive analysis and tips. By using the coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 9 additional InvestingPro Tips available, investors can gain a more detailed understanding of the company's strategic positioning and financial trajectory.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.